Pre-clinical evaluation of potential cytokine release syndrome and efficacy of a BCMAxCD3 bispecific antibody in humanized mice

Bispecific antibodies (BsAbs) are now emerging as the next promising class of immunotherapies.

As BsAbs can have significant adverse effects such as cytokine release syndrome (CRS), the Jackson Laboratory decided to evaluate the CRS related safety profile, in addition to efficacy, of this BCMAxCD3 BsAb in pre-clinical studies.